Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT05477784 Recruiting - Cancer Clinical Trials

Cancer Parenting Program for the Enhancement of the Quality of Life of Patients With Advanced Cancer and Their Children

EC-PC
Start date: July 19, 2022
Phase: N/A
Study type: Interventional

This trial examines the usefulness of two educational programs for parents with late-stage cancer who have a 5 - 17 year old child. The programs are designed to enhance the quality of the parent-child relationship and add to the parent's confidence in managing the impact of their cancer on their child. Educational programs may reduce anxiety and depression and improve the well-being and quality of life of parents with advanced cancers and their children. Recruitment occurs nationally via referral to the Fred Hutch/University of Washington Cancer Consortium team.

NCT ID: NCT05474846 Recruiting - Depression Clinical Trials

Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer

Start date: November 21, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To learn if Cognitive Behavior Therapy (called CBT), combined with either Bright Light Therapy (called BLT), methylphenidate, and/or melatonin, can help improve sleep and other related symptoms such as fatigue, anxiety, and depression in cancer patients. This is an investigational study. In this study, BLT, Methylphenidate and Melatonin will be compared to their placebos.

NCT ID: NCT05472714 Recruiting - Cancer Clinical Trials

Educational Video for Genetic Testing

Start date: September 10, 2021
Phase: N/A
Study type: Interventional

Develop and evaluate the acceptability, feasibility, and preliminary efficacy of an informational video on paired tumor/normal testing for children and adolescents with a new diagnosis of cancer, tumors or other diagnosis.

NCT ID: NCT05470010 Recruiting - Cancer Clinical Trials

Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors

SEAMLESS
Start date: June 30, 2024
Phase: N/A
Study type: Interventional

There is a need to develop, evaluate, and disseminate self-directed, easily accessible, safe, affordable, and effective psychosocial interventions to people living with cancer (PLWC) post-treatment. Smartphone app-based health interventions are an innovative way to deliver psychosocial cancer-care. The Mindfulness-Based Cancer Survivorship (MBCS) Journey app is a mobile app format of the Mindfulness-based Cancer Recovery program. In the SEAMLESS Study, the investigators aim to evaluate the MBCS Journey app (a 4 week mind-body intervention) in cancer survivors post-treatment. This is a randomized wait-list controlled trial. Participants will either be assigned into the immediate group (will receive intervention immediately after enrollment) or the waitlist group (wait for 3 months before receiving the intervention).

NCT ID: NCT05467189 Recruiting - Cancer Clinical Trials

Antineoplastic Drugs in Elderly Patients

Start date: January 1, 2021
Phase:
Study type: Observational [Patient Registry]

The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend optimized dosage regimens.

NCT ID: NCT05466994 Recruiting - Cancer Clinical Trials

A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)

Start date: August 19, 2022
Phase: Phase 2
Study type: Interventional

To learn if playing an augmented reality game called SpellBound can reduce pain and the need for opioids in young patients scheduled for surgery.

NCT ID: NCT05465161 Recruiting - Cancer Clinical Trials

STING MARK Universal Fiducial Marker System

StingMark
Start date: February 28, 2022
Phase: N/A
Study type: Interventional

Currently available fiducial marker and fiducial insertion strategies are rudimentary, imprecise, not compatible with multiple insertion catheters/needles and are overall unreliable. STING-MARK device is the first universal, fully detachable and non-premounted radiopaque fiducial device system. Allowing biopsy prior to insertion, STING-MARK is easily and reliably delivered through-the-needle to the tumor, in order to accurately pinpoint its location for image-guided therapies. This study aims at establishing proof of concept for STING-MARK, by demonstrating its usability, reproducibility, radio-opacity and retention in a variety of clinically-relevant ex vivo organ samples.

NCT ID: NCT05456100 Recruiting - Cancer Clinical Trials

Chinese American Cancer Survivors Writing Study

Start date: July 14, 2022
Phase: N/A
Study type: Interventional

The Chinese American Cancer Survivors Writing Study is a Randomized Controlled Trial (RCT) testing the feasibility and efficacy of the Expressive Helping (EH) intervention among Chinese American cancer survivors.

NCT ID: NCT05454280 Recruiting - Cancer Clinical Trials

Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)

Start date: October 14, 2022
Phase: Phase 3
Study type: Interventional

This is a randomized trial of intensified post-discharge surveillance (Intervention Arm) versus standard post-discharge surveillance (Control Arm).

NCT ID: NCT05443737 Recruiting - Cancer Clinical Trials

Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients

Start date: January 1, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of a multi-component intervention to improve young cancer survivors' engagement in goal-concordant oncofertility care, concurrently with observing and gathering information on how the intervention is implemented. The investigators hypothesize that implementation of the intervention will result in increased young cancer survivors' engagement in goal-concordant oncofertility care.